Published in Chem Biol Interact on February 01, 1979
Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A (1993) 1.91
Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A (1994) 1.75
Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A (1994) 1.50
Effect of adriamycin on heart mitochondrial DNA. Biochem J (1987) 0.88
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Skin graft for 2-stage treatment of severe hypospadias: back to the future? J Urol (2002) 1.77
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci (2002) 1.65
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep (1969) 1.56
A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol (1992) 1.42
Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol (2005) 1.39
Interaction of daunomycin and its derivatives with DNA. Biochim Biophys Acta (1972) 1.34
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest (2000) 1.30
Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta (1992) 1.29
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res (1992) 1.29
Prenatal diagnosis and clinical outcome of ovarian cysts. J Pediatr Surg (1992) 1.21
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry (1990) 1.20
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate (2001) 1.18
The interaction of adriamycin and its beta anomer with DNA. Biochim Biophys Acta (1977) 1.16
Mechanism of action of daunomycin. Acta Genet Med Gemellol (Roma) (1968) 1.16
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol (1998) 1.15
Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A (1997) 1.15
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14
Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol (2000) 1.13
Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets (2003) 1.12
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res (2000) 1.06
Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells. Int J Cancer (1986) 1.01
Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem (2001) 1.01
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta (1995) 1.00
Development of humanized mice for the study of hepatitis C virus infection. Transplant Proc (2006) 1.00
Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Mol Pharmacol (1996) 0.99
A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer (2001) 0.98
[Atypical metastatic site of lung adenocarcinoma]. Rev Pneumol Clin (2011) 0.98
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol (1999) 0.96
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene (1992) 0.96
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res (2001) 0.96
A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer (1999) 0.96
Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer (1996) 0.96
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res (2001) 0.95
ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem (2009) 0.95
Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer (1996) 0.95
Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation status. J Cell Sci (2000) 0.95
Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep (1972) 0.94
DNA topoisomerase-trapping antitumour drugs. Eur J Cancer (1992) 0.94
Antenatal diagnosis of congenital anomaly: a really traumatic experience? J Perinatol (2011) 0.94
[Lipoleiomyoma of the uterus]. Pathologica (1997) 0.94
Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol (1971) 0.94
Mechanisms of cellular resistance to camptothecins. Curr Med Chem (2006) 0.94
The importance of gastric emptying in reflux esophagitis: an experimental research on pigs. J Surg Res (1987) 0.94
Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori (1989) 0.93
Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res (1986) 0.93
Mechanism of resistance to anthracyclines and vinca alkaloids. Prog Clin Biol Res (1983) 0.93
Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int J Cancer (1990) 0.92
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem (2001) 0.92
Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis (1997) 0.92
A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res (1999) 0.92
MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer (1995) 0.92
Inhibiting effect of the new cytotoxic antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells. J Cell Biol (1965) 0.92
Global gene expression of fission yeast in response to cisplatin. Cell Mol Life Sci (2004) 0.91
Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res (2000) 0.91
Specific inhibition of DNA-polymerases from RNA tumor viruses by some new daunomycin derivatives. FEBS Lett (1972) 0.91
Endogenous oxidative stress induces distinct redox forms of tumor necrosis factor receptor-1 in melanoma cells. Ann N Y Acad Sci (2004) 0.90
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst (1997) 0.90
New developments in antitumor anthracyclines. Pharmacol Ther (1998) 0.89
The interaction of daunorubicin and doxorubicin with DNA and chromatin. Biochim Biophys Acta (1980) 0.89
Preparation and biological evaluation of 4-O-demethyldaunorubicin (carminomycin I) and of its 13-dihydro derivative. J Antibiot (Tokyo) (1978) 0.89
Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: sequence specificity and structural drug determinants. Cancer Res (1997) 0.89
Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol (1988) 0.89
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol (1998) 0.89
Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem Biol Interact (1977) 0.88
Stenting for caustic strictures: esophageal replacement replaced. J Pediatr Surg (1998) 0.88
Comparison of antitumor effects of daunorubicin covalently linked to poly-L-amino acid carriers. Eur J Cancer Clin Oncol (1984) 0.88
Combined immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Biomedicine (1973) 0.88
Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol (1994) 0.88
Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol (1997) 0.88
The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J Inorg Biochem (1999) 0.88
Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs (1994) 0.87
Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci (2003) 0.87
Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res (1977) 0.87
Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry (1993) 0.87
Daunomycin pharmacological activity at the cellular level. Pathol Biol (1967) 0.87
Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes. Int J Cancer (1994) 0.87
Exteriorization-aspiration minilaparotomy for treatment of neonatal ovarian cysts. J Pediatr Adolesc Gynecol (2002) 0.86
The inhibition in vitro of DNA polymerase and RNA polymerases by daunomycin and adriamycin. Biochem Pharmacol (1975) 0.86
Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers. Biochemistry (1993) 0.86
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res (2001) 0.86
Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Mol Pharmacol (1998) 0.86
Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differ (2002) 0.86
Validation of double gradient denaturing gradient gel electrophoresis through multigenic retrospective analysis. Clin Chem (1999) 0.86
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol (2013) 0.86
Evaluation of hypertension and related target organ damage by average day-time blood pressure. Clin Exp Hypertens A (1985) 0.86
gamma-Glutamyl transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney. Eur J Cancer (2003) 0.85